UK’s NICE Not Convinced By Cannabis-Based Medicines

New draft guidance from the health technology assessment body NICE says that more evidence is needed on cannabis-based medicines before they can be more widely used. In the meantime, it says they should not be used in chronic pain, epilepsy or spasticity in multiple sclerosis, while nabilone may be used for chemotherapy-related sickness.

Cannabis
NICE does not recommend cannabis-based medicines for pain, spasticity or epilepsy

NICE, the health technology assessment body for England and Wales, has issued a new draft guideline that recommends against using cannabis-based medicines to treat chronic pain because they are of only “modest” efficacy in this indication.

It says that GW Pharmaceuticals’ Sativex (cannabidiol spray) should not be used for treating spasticity in multiple sclerosis because it...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe